Intralesional Injection Of Methotrexate Versus Triamcinolone Acetonid In Treatment Of Localized Psoriasis

Efficacy Of Intralesional Injection Of Methotrexate Versus Triamcinolone Acetonid In Treatment Of Localized Psoriasis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05408208

Enrollment

Registered

2022-06-07

Start date

2022-05-21

Completion date

2023-05-21

Last updated

2022-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Localized Psoriasis

Keywords

Intralesional Injection ,Methotrexate, localized Psoriasis

Brief summary

The aim of the present study is to evaluate the efficacy of intralesional injection of methotrexate in comparison with Intralesional Injection of Triamcinolone Acetonid in localized psoriasis (body surface area \< 10%) .

Detailed description

study enrolling 30 patients of localized psoriasis. 15 patients received intralesional methotrexate : * Taking aseptic condition ,One psoriatic plaque will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm2. * Another plaque will treated with intralesional ingection of distilled water as controlled plaque. * patient will receive oral folic acid 5mg tablet every day except the day of injection. Other 15 patients received intralesional trimethinolone acetonide: * Taking aseptic condition , One plaque will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . * another plaque will treated with Intralesional injection of distilled water as controed plaque. * Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

Interventions

DRUGIntralesional Injection of Methotrexate

One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque. Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

DRUGTriamcinolone Acetonid

One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with localized Psoriasis (body surface area\<10%)

Exclusion criteria

* Patient refusal. Generalized psoriasis. Pregnancy. Lactation. Immunocompromised patients . Patients with history of hypersensitivity to methotrexate. Patients with other inflammatory skin disorders. Patients with chronic hepatic, renal , pulmonary ,or haematological disorders. patients on treatment for psoriasis .

Design outcomes

Primary

Measure	Time frame	Description
Efficacy Of Intralesional Injection Of Methotrexate Versus Triamcinolone Acetonid In Treatment Of Localized Psoriasis	3 months after treatment	clinical and dermoscopic changes according to psoriasis area severity index

Countries

Egypt

Contacts

Primary ContactGehad Hamdy

gehad011074@med.sohag.edu.eg01104269431

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026